Table 2.
LTUC | UTUC | |||
---|---|---|---|---|
O/E | SIR40–84 (95 %CI) | O/E | SIR40–84 (95 %CI) | |
Male | ||||
1998 | 16/2.7 | 5.9 (3.6–9.7) | 7/0.5 | 13.0 (6.2–27.3) |
1999 | 27/6.0 | 4.5 (3.0–6.6) | 18/1.3 | 13.9 (8.8–22.1) |
2000 | 48/5.7 | 8.4 (6.4–11.2) | 19/1.6 | 12.2 (7.8–19.1) |
2001 | 43/6.8 | 6.3 (4.7–8.5) | 28/2.2 | 12.9 (8.9–18.7) |
2002 | 68/8.4 | 8.1 (6.4–10.3) | 34/2.9 | 11.9 (8.5–16.6) |
2003 | 65/10.5 | 6.2 (4.8–7.9) | 49/3.5 | 13.9 (10.5–18.4) |
2004 | 63/12.5 | 5.1 (4.0–6.5) | 53/4.1 | 12.8 (9.8–16.8) |
2005 | 61/13.7 | 4.5 (3.5–5.8) | 35/4.9 | 7.2 (5.2–10.0) |
2006 | 74/14.0 | 5.3 (4.2–6.6) | 52/5.5 | 9.4 (7.2–12.3) |
2007 | 79/14.7 | 5.4 (4.3–6.7) | 58/6.1 | 9.5 (7.3–12.3) |
2008 | 83/16.6 | 5.0 (4.0–6.2) | 65/5.8 | 11.2 (8.8–14.2) |
Female | ||||
1998 | 12/1.3 | 9.0 (5.1–15.8) | 11/0.8 | 14.3 (7.9–25.8) |
1999 | 29/3.1 | 9.5 (6.6–13.7) | 20/1.8 | 10.9 (7.1–16.9) |
2000 | 36/3.3 | 10.8 (7.8–14.9) | 47/2.7 | 17.7 (13.3–23.6) |
2001 | 49/3.9 | 12.6 (9.5–16.6) | 56/3.1 | 18.4 (14.1–23.9) |
2002 | 76/5.1 | 14.8 (11.8–18.5) | 57/4.1 | 13.9 (10.7–18.0) |
2003 | 83/5.5 | 15.1 (12.1–18.7) | 83/5.0 | 16.5 (13.3–20.4) |
2004 | 89/6.7 | 13.3 (10.8–16.4) | 94/5.7 | 16.6 (13.5–20.3) |
2005 | 118/7.3 | 16.1 (13.5–19.3) | 93/6.8 | 13.7 (11.2–16.8) |
2006 | 136/8.3 | 16.4 (13.9–19.5) | 113/7.8 | 14.5 (12.1–17.4) |
2007 | 121/7.4 | 16.3 (13.7–19.5) | 107/7.9 | 13.5 (11.2–16.3) |
2008 | 100/8.3 | 12.0 (9.9–14.6) | 116/8.5 | 13.6 (11.4–16.4) |
LTUC: lower urinary tract urothelial cancer; UTUC: upper urinary tract urothelial cancer; and SIR: standard incidence rate.